Toward Panvigilance for Medicinal Product Regulation: Clinical Trial Design Using Extremely Discordant Biomarkers

Alberts B . (2012). The end of “Small Science”?. Science, 337, 1583.

Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther, 69, 89–95.

Kalow W , Ozdemir V , Tang BK , Tothfalusi L , and Endrenyi L . (1999). The science of pharmacological variability: An essay. Clin Pharmacol Ther, 66, 445–447.

Kalow W , Ozdemir V , and Tothfalusi L . (2001). Multigenic traits and risk assessment in pharmacology: A population approach. Pharmacogenomics J, 1, 234–236.

Nebert DW . (2000). Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol, 410, 107–120.

Özdemir V . (2018a). The Dark Side of the Moon: The Internet of Things, Industry 4.0, and The Quantified Planet. OMICS, 22, 637–641.

Özdemir V . (2018b). Precision medicine goes global: How to get it right? Four ways to mobilize scientific knowledge. OMICS, 22, 539–543.

Özdemir V . (2019a). Not all intelligence is artificial: Data science, automation and AI meet HI. OMICS, 23, 67–69.

Özdemir V . (2019b). Towards an “ethics-of-ethics” for responsible innovation. In: Handbook of Responsible Innovation. A Global Resource. von Schomberg R, and Hankins J, eds. Cheltenham, UK: Edward Elgar Publishing, (in press).

Özdemir V , Kalow W , Tothfalusi L , et al. (2005). Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics, 3, 53–71.

Ravetz J . (2016). How should we treat science's growing pains?. The Guardian, June 8th.

Read M . (2018). How Much of the Internet Is Fake? Turns Out, a Lot of It, Actually. New York Magazine (Intelligencer) December 26th.

Rip A . (2016). The clothes of the emperor. An essay on RRI in and around Brussels. J Respons Innov, 3, 290–304.

Sarewitz D . (2016). Saving Science. The New Atlantis 49 (Spring/Summer), 4–40.

Stilgoe J , Lock SJ , and Wilsdon J . (2014). Why should we promote public engagement with science?. Public Underst Sci, 23, 4–15.

Thoreau F , and Delvenne P . (2012). Have STS fallen into a political void? Depoliticisation and engagement in the case of nanotechnologies. Politica Sociedade, 11, 205–226.

von Schomberg R . (2013). A vision of responsible research and innovation. In: Responsible Innovation. Owen R, Bessant J, and Heintz M, eds. USA: Wiley, pp. 51–74.

WHO. (2004). Pharmacovigilance: Ensuring the Safe Use of Medicines. Geneva: World Health Organization.

WHO. (2006). The Safety of Medicines in Public Health Programmes: Pharmacovigilance an Essential Tool. Geneva: World Health Organization.